The oral semaglutide research pipeline is more active in 2026 than the injectable pipeline because oral has more headroom to grow into new indications. The two most important recent developments are the SOUL cardiovascular outcomes trial (announced late 2024, published 2025) which established a definitive cardiovascular benefit for oral semaglutide, and the OASIS obesity trial program which is producing approval pathways for high-dose oral semaglutide for obesity.<\/p>\n
Beyond these major programs, oral semaglutide is being studied in Alzheimers disease (the evoke and evoke+ trials), in metabolic dysfunction-associated steatohepatitis (MASH), and in earlier-stage type 2 diabetes prevention. The next 2-3 years are likely to substantially expand the FDA-approved use cases for oral semaglutide.<\/p>\n
This article walks through the current state of oral semaglutide research and what to expect.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The SOUL trial (Semaglutide cardiOvascular oUtcomes triaL) was the dedicated cardiovascular outcomes trial for oral semaglutide 14 mg in patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease.<\/strong> The trial randomized approximately 9,650 patients to oral semaglutide or placebo on top of standard care, with results published in 2025.<\/p>\n Quick Answer: SOUL trial (2024-2025) confirmed cardiovascular benefit of oral semaglutide 14 mg in type 2 diabetes<\/p>\n SOUL showed a statistically significant reduction in major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo. The effect size was similar to what injectable semaglutide had shown in SUSTAIN-6 and SELECT (roughly 20% MACE reduction). The trial also showed renal benefits and reductions in heart failure hospitalizations.<\/p>\n This confirms that the cardiovascular benefit of semaglutide is independent of the delivery route. The FDA approved a cardiovascular risk reduction indication for Rybelsus\u00ae based on SOUL data.<\/p>\n The OASIS program tests high-dose oral semaglutide (25 mg and 50 mg daily) specifically for obesity in non-diabetic patients.<\/strong> OASIS 1 (Knop et al. 2023 Lancet) randomized 667 adults with obesity to oral semaglutide 50 mg daily or placebo for 68 weeks.<\/p>\n OASIS 1 results: weight loss of 17.4% with semaglutide 50 mg versus 1.8% with placebo. This compares favorably with injectable Wegovy\u00ae 2.4 mg, which produced 14.9% weight loss in STEP 1 (Wilding 2021 NEJM). The side effect profile was acceptable, with GI adverse events similar to other GLP-1 dosing in obesity trials.<\/p>\n OASIS 4 (Wadden 2024 Nature Medicine) tested oral semaglutide 25 mg in patients with obesity and showed 13.6% weight loss at 64 weeks. The lower dose still produces substantial weight loss but less than 50 mg.<\/p>\n FDA approval for high-dose oral semaglutide for obesity is expected in 2026 based on the OASIS data, which will create a true oral alternative to Wegovy.<\/p>\n For patients in 2026, the implications are: oral semaglutide is now FDA-approved for cardiovascular risk reduction in type 2 diabetes (similar to injectable Ozempic\u00ae), high-dose oral semaglutide for obesity is becoming available, and the choice between oral and injectable is increasingly about preference rather than efficacy ceiling.<\/strong><\/p>\n The persistent advantage of injectable is convenience for patients who dont mind injections (no daily fasting routine). The persistent advantage of oral is convenience for patients who prefer pills.<\/p>\n The cost gap has narrowed because high-dose oral semaglutide will be priced similarly to Wegovy.<\/p>\n evoke and evoke+ are phase 3 trials testing oral semaglutide 14 mg daily for slowing cognitive decline in patients with early Alzheimers disease.<\/strong> Results are expected in 2025-2026. The trials enroll approximately 1,840 patients each, randomized to semaglutide or placebo for 156 weeks.<\/p>\n The mechanistic rationale for GLP-1 in Alzheimers includes reduced neuroinflammation, improved insulin sensitivity in the brain (relevant to the type 3 diabetes hypothesis of Alzheimers), and reduced amyloid pathology in animal models. Smaller exploratory trials of liraglutide and exenatide have shown mixed cognitive results.<\/p>\n If evoke shows a clinical benefit, it would be a major medical breakthrough. There is no current Alzheimers treatment that meaningfully slows cognitive decline beyond modest effects from approved anti-amyloid antibodies.<\/p>\n The exenatide phase 3 trial for Parkinsons (EXENATIDE-PD3, Vijiaratnam 2024 Lancet) recently failed to show motor benefit, which has tempered expectations for GLP-1 neurodegeneration research. But Alzheimers is mechanistically different from Parkinsons, so the trials are testing distinct hypotheses.<\/p>\n Newsome et al. 2021 NEJM showed injectable semaglutide phase 2 results for non-alcoholic steatohepatitis with 59% NASH resolution. The ESSENCE phase 3 trial is the dedicated semaglutide MASH trial with results expected in 2026.<\/p>\n Oral semaglutide is also being explored for MASH, though the injectable program is further along. If injectable semaglutide receives MASH approval, oral may follow on similar evidence.<\/p>\n MASH affects roughly 5% of US adults and is becoming a leading cause of liver disease. Effective MASH treatment would be a major unmet need. Tirzepatide (SYNERGY-NASH phase 2) and resmetirom (MAESTRO-NASH, Harrison 2024 NEJM) are also being developed for MASH.<\/p>\n Yes. The hypothesis is that oral semaglutide in patients with prediabetes could prevent progression to type 2 diabetes, building on the DPP (Diabetes Prevention Program) findings that lifestyle intervention reduces diabetes risk by 58%. Semaglutide could provide pharmacologic prevention for patients who cant achieve enough lifestyle change.<\/p>\n Whether this becomes an FDA-approved indication depends on trial design and outcomes. The cost-effectiveness analysis for treating millions of prediabetic adults with a $1,000\/month drug is challenging.<\/p>\n Key Takeaway: PIONEER 6 (Husain 2019 NEJM) established cardiovascular safety in earlier era<\/p>\n The FLOW trial (Perkovic et al.<\/strong> 2024 NEJM) established injectable semaglutide for diabetic kidney disease with a 24% reduction in kidney failure or cardiovascular death. Oral semaglutides SOUL trial also showed renal benefits in a broader population.<\/p>\n Oral semaglutide is not yet approved for a dedicated kidney disease indication, but the evidence is moving in that direction. Patients with type 2 diabetes and CKD are increasingly candidates for GLP-1 therapy as a renoprotective strategy.<\/p>\n The current Rybelsus formulation uses SNAC as the absorption enhancer.<\/strong> Novo Nordisk and other companies are exploring next-generation oral GLP-1 formulations with potentially higher bioavailability or simpler dosing schedules.<\/p>\n Oral small-molecule GLP-1 agonists (not peptides) are also being developed. Eli Lillys orforglipron is the most advanced of these, with phase 3 trials underway. Orforglipron is taken orally without the fasting requirement and has shown weight loss comparable to oral semaglutide in early trials.<\/p>\n If orforglipron receives approval, it could compete directly with Rybelsus, particularly for patients who find the fasting requirement challenging.<\/p>\n Pediatric obesity trials with injectable semaglutide (STEP TEENS) led to Wegovy approval for ages 12+.<\/strong> Oral semaglutide pediatric trials are likely to follow but have not yet produced approval.<\/p>\n For pediatric type 2 diabetes, the standard options remain metformin first-line, with liraglutide and exenatide having pediatric approvals. Oral semaglutide pediatric approval would expand options.<\/p>\n The pipeline includes oral small-molecule GLP-1 agonists (orforglipron), triple agonists targeting GLP-1, GIP, and glucagon receptors (retatrutide), and various combination drugs.<\/strong> Some of these may eventually surpass oral semaglutide for weight loss or convenience.<\/p>\n Retatrutide phase 2 (Jastreboff 2023 NEJM) showed 24% weight loss at 48 weeks, more than any approved drug. If phase 3 confirms this, retatrutide would set a new standard for weight loss medications.<\/p>\n For now, oral semaglutide remains a leading oral GLP-1 option, particularly with the SOUL cardiovascular data and the upcoming OASIS obesity approval.<\/p>\n For current Rybelsus users, the SOUL data means your medication has now established cardiovascular benefit on top of glycemic control.<\/strong> This may influence insurance coverage decisions and your prescribers willingness to maintain Rybelsus long-term.<\/p>\n The upcoming high-dose oral semaglutide for obesity (25 mg or 50 mg) provides an oral pathway for more weight loss if needed. Patients on Rybelsus 14 mg who want more weight loss may eventually be able to escalate to higher oral doses rather than switching to injection.<\/p>\n Bottom line: Pipeline includes oral semaglutide for MASH and earlier-stage diabetes prevention<\/p>\n Based on SOUL trial data, yes. The FDA added a cardiovascular indication to Rybelsus following SOUL.<\/p>\n Expected FDA approval in 2026 based on the OASIS trial program.<\/p>\n OASIS 1 (Knop 2023 Lancet) showed 17.4% weight loss at 68 weeks, comparable to injectable Wegovy 2.4 mg.<\/p>\n Yes, the evoke and evoke+ trials are phase 3 trials with results expected in 2025-2026.<\/p>\n Oral semaglutide is being explored for MASH, though the injectable program (ESSENCE trial) is more advanced.<\/p>\n Patent expirations are expected in the early 2030s.<\/p>\n Retatrutide (GLP-1\/GIP\/glucagon triple agonist) is the most exciting weight-loss agent in development. Orforglipron is the most exciting oral GLP-1.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Introduction The oral semaglutide research pipeline is more active in 2026 than the injectable pipeline because oral has more headroom to grow into new…<\/p>\n","protected":false},"author":11,"featured_media":93185,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Oral Semaglutide Latest Research: New Indications, Trials and Whats Coming","_yoast_wpseo_metadesc":"The oral semaglutide research pipeline is more active in 2026 than the injectable pipeline because oral has more headroom to grow into new indications....","_yoast_wpseo_focuskw":"oral semaglutide latest","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[8],"tags":[41,46],"class_list":["post-90315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ozempic","tag-research","tag-semaglutide"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90315"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90315\/revisions"}],"predecessor-version":[{"id":92470,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90315\/revisions\/92470"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93185"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What About the OASIS Obesity Trials?<\/h2>\n
What Does This Mean for Patients in 2026?<\/h2>\n
What Is the Evoke Trial in Alzheimers?<\/h2>\n
What About MASH (NASH) Trials?<\/h2>\n
Is Oral Semaglutide Being Tested for Prediabetes?<\/h2>\n
What About Kidney Disease Specifically?<\/h2>\n
Are There New Oral Semaglutide Formulations in Development?<\/h2>\n
What About Pediatric Trials for Oral Semaglutide?<\/h2>\n
How Does Oral Semaglutide Compare with the Most Exciting Pipeline Drugs?<\/h2>\n
What Should Current Rybelsus Users Know?<\/h2>\n
FAQ<\/h2>\n
Is Rybelsus Now Approved for Cardiovascular Risk Reduction?<\/h3>\n
When Will High-dose Oral Semaglutide for Obesity Be Available?<\/h3>\n
How Much Weight Does Oral Semaglutide 50 Mg Produce?<\/h3>\n
Is Oral Semaglutide Being Tested for Alzheimers?<\/h3>\n
What About MASH?<\/h3>\n
Will Oral Semaglutide Go Generic Soon?<\/h3>\n
Whats the Most Exciting GLP-1 Development Overall?<\/h3>\n